Leo Pharma will retain thrombosis business despite goal to focus on dermatology
![Leo Pharma is struggling with a growing bottom line deficit, but according to Anders Kronborg, CFO and acting CEO until April, the ship will be turned around in 2023 | Photo: Leo Pharma / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13832885.ece/ALTERNATES/schema-16_9/doc7k5bzkplvb81jqc5g6wl.jpg)
Leo Pharma wants to become one of the world’s biggest dermatology firms by 2030. To that end, the Danish pharmaceutical firm has laid out a strategy to streamline the business and focus efforts within the dermatology area.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Layoffs and restructuring will prepare Leo Pharma for IPO
For subscribers
Leo Pharma disappoints as deficit surpasses USD 720m
For subscribers